Urinary G3BP as a Novel Biomarker in Lupus Nephritis

NCT06520670 | Not Yet Recruiting

• 1 other identifier: Urinary G3BP in LN
• Study Type: observational
• Target: 70
• Locations: 0 countries
• Sites: N/A

Brief Summary

Estimation of urinary Galectin-3 binding protein (u-Gal-3BP) in patients with systemic lupus erythematosus with and without lupus nephritis and in glomerulonephritis for other kidney diseases, Find the relation of urinary Galectin-3 binding protein (u-Gal-3BP) levels with lupus nephritis, and Correlate urinary Galectin-3 binding protein (u-Gal-3BP) levels with SLE disease activity

Conditions

Lupus Nephritis

Outcome Measures

Primary Outcomes (1)

• Level of galectin_3 binding protein in urine samples .

  Level of galectin\_3binding protein in urine samples by pg/mmol using ELISA in patient with lupus nephritis.

  baseline

Study Arms (3)

Patient with Lupus nephritis diagnosed by biopsy.

Diagnostic Test: Urinary galectin-3 binding protein

Patient with SLE without nephritis.

Diagnostic Test: Urinary galectin-3 binding protein

Patient with nephritis of other reasons

Patient with nephritis of other reasons; acute proliferative glomerulonephritis (postinfectious and infection associated), crescentic glomerulonephritis, else.

Diagnostic Test: Urinary galectin-3 binding protein

Interventions

Urinary galectin-3 binding protein DIAGNOSTIC_TEST

Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.

Patient with Lupus nephritis diagnosed by biopsy.; Patient with SLE without nephritis.; Patient with nephritis of other reasons

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

males and females that are not pregnant of any age above 18 years have one of next criteria: * Patient with Lupus nephritis diagnosed by biopsy. * Patient with SLE without nephritis. * Patient with nephritis of other reasons; acute proliferative glomerulonephritis (postinfectious and infection associated), crescentic glomerulonephritis, else. All patients were selected from outpatient clinic of rheumatology and inpatient wards of Internal Medicine Department Assiut University Hospitals. The patients will be interviewed, and those who agreed to share in the study were selected. An informed consent was obtained from each patient to be enrolled in the study.

You may qualify if:

• Any age above 18 years.
• Patient with Lupus nephritis diagnosed by biopsy.
• Patient with SLE without nephritis.
• Patient with nephritis of other reasons; acute proliferative glomerulonephritis (postinfectious and infection associated), crescentic glomerulonephritis, else.

You may not qualify if:

• Pregnant.
• Patient who refused to be part of the study.
• Patients with estimated Glomerular Filtration Rate less than 15ml/min

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Lupus Nephritis

Condition Hierarchy (Ancestors)

Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Lupus Erythematosus, Systemic; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Azza Mh Hussien, master

CONTACT

01063676298; azzaelkady1010@gmail.com

Rasha Ah madkor

CONTACT

01090895666; rashaahmed@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: July 20, 2024
• First Posted: July 25, 2024
• Study Start: September 1, 2024
• Primary Completion: September 1, 2025
• Study Completion: October 1, 2025
• Last Updated: July 26, 2024

Record last verified: 2024-07